Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials

Documenti analoghi

• Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
  di: Antonio Pinto, et al.
  Pubblicazione: (2024)
• How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
  di: Nayla Mouawad, et al.
  Pubblicazione: (2024)
• Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
  di: Beatrice Casadei, et al.
  Pubblicazione: (2024)
• Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
  di: Kaitlin Annunzio, et al.
  Pubblicazione: (2024)
• Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
  di: Evgenia Verrou, et al.
  Pubblicazione: (2024)